An oral TYK2 inhibitor held its psoriatic arthritis response through a year

Design

randomised, double-blind, placebo-controlled phase 3 trial with crossover at week 16

Population

670 biologic-naive adults with active psoriatic arthritis, hs-CRP ≥3 mg/L and at least one radiographic hand or foot erosion

Primary outcome

ACR20 response at week 16

Effect

54.2% against 34.1% (P<0.001), maintained and increased to week 52; serious adverse events 1.8% against 2.4%; no deaths

POETYK PsA-1 randomised 670 biologic-naive adults with active psoriatic arthritis 1:1 to oral deucravacitinib 6 mg once daily or placebo for 16 weeks, after which the placebo group crossed over. Entry required a high-sensitivity CRP of at least 3 mg/L and at least one radiographic hand or foot erosion - a population with objectively active, erosive disease rather than symptoms alone.

ACR20 at week 16 was 54.2% with deucravacitinib against 34.1% with placebo (P<0.001). Responses rose further by week 52, and patients who crossed over at week 16 caught up with those on continuous treatment. Structural damage inhibition was seen at both 16 and 52 weeks, though by post hoc analysis. Safety was the notable part: serious adverse events in 1.8% against 2.4% at week 16, discontinuations for adverse events in 2.4% against 1.8%, both remaining low to a year, with no imbalance in cardiovascular events, malignancies or opportunistic infections, and no deaths.

Deucravacitinib inhibits tyrosine kinase 2 through an allosteric mechanism distinct from the JAK1/2/3 inhibitors, and the safety profile in this trial is consistent with the claim that it does not carry the same class concerns - but a 670-patient trial cannot exclude rare events, and the cardiovascular and malignancy signals that constrain JAK inhibitor use emerged from far larger and longer datasets. What it offers today is an oral option with a placebo-controlled ACR20 gain of 20 percentage points in biologic-naive erosive disease, for patients who cannot or will not take an injectable. Availability and cost in India are the immediate limits; there is no CDSCO position on this indication that this trial reflects.

• Consider an oral TYK2 inhibitor where injectable biologics are refused or impractical, in biologic-naive active psoriatic arthritis
• Note the trial population: raised CRP and at least one erosion, so the results apply to objectively active disease
• Do not present the safety profile as established - a 670-patient year cannot exclude the rare events that shaped JAK inhibitor labelling
• Point out to patients that those who started 16 weeks late caught up, so there is no penalty for a trial of conventional treatment first
• Check availability, indication and cost locally before raising it as an option

Why it matters

It puts an oral drug with a year of data into a space where the alternatives are injections.

Don't overread it

Placebo control lasted 16 weeks, structural damage analysis was post hoc, and 670 patients over a year cannot establish the long-term safety profile of a new kinase inhibitor class.

The statistics, in plain English

An ACR20 of 54.2% against 34.1% is a 20 percentage point absolute gain, meaning roughly five patients treated for one additional 20% responder - respectable for psoriatic arthritis, and worth noting that ACR20 is a low bar representing 20% improvement rather than remission. The week 52 figures come from a period when everyone was receiving the drug, so they show maintenance rather than a continuing comparison against placebo. Structural damage inhibition was assessed post hoc, which means it was not the prespecified analysis and should be weighted accordingly.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.